We described the development and validation of the dual modal model (MP‐NN) integrating SMFs with tumor marker CEA (Figure 2A), and demonstrated that MP‐NN had better performance than single modal Met‐NN and CEA in screening of early LUAD patients from controls (Figure 2B–H). This evidence concerns the gene CEACAM5 and neoplasm.